Stay updated on Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial

Sign up to get notified when there's something new on the Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 54 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.3%
    Check dated 2024-07-23T15:20:44.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.1%
    Check dated 2024-07-16T08:23:19.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-07-02T14:41:51.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has changed from v2.9.3 to v2.9.5, indicating an update or modification to the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-27T10:11:07.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.
    Difference
    0.1%
    Check dated 2024-06-26T08:59:40.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has recently changed to 'Show less MedlinePlus related topics: Psoriasis Drug Information available for: Apremilast FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Randomized Interventional Model : Parallel Assignment Masking : Single ( Outcomes Assessor ) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Risankizumab Risankizumab 150 mg as a single subcutaneous (SC) injection at at Baseline (Day 1) and Week 4 (Period A) and at Weeks 16, 28, and 40 (Period B). Drug : Risankizumab Subcutaneous injection Other Names: ABBV-066 Skyrizi Experimental : Apremilast Participants receive apremilast 30 mg orally twice daily (BID) in Period A and re-randomized to receive either risankizumab 150 mg as a single SC injection at Weeks 16, 20, 32 in Period B or apremilast 30 mg orally BID from Week 16 up to Week 52 in Period B. For those taking apremilast in Period B, non-responders at Week 28 and Week 40 will be offered to receive risankizumab as rescue medication. Drug : Risankizumab Subcutaneous injection Other Names: ABBV-066 Skyrizi Drug : Apremilast Oral Tablets Other Names: Otezla'
    Difference
    47%
    Check dated 2024-06-25T08:35:44.000Z thumbnail image

Stay in the know with updates to Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Psilocybin for Depression/Anxiety in Parkinson's Disease Clinical Trial page.